The estimated Net Worth of Camille L Bedrosian is at least $4.18 millió dollars as of 21 June 2024. Camille Bedrosian owns over 3,000 units of Ultragenyx Pharmaceutical stock worth over $168,990 and over the last 7 years he sold RARE stock worth over $1,509,550. In addition, he makes $2,496,820 as Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical.
Sign up
Camille Bedrosian RARE stock SEC Form 4 insiders trading
Camille has made over 12 trades of the Ultragenyx Pharmaceutical stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of RARE stock worth $168,990 on 21 June 2024.
The largest trade he's ever made was exercising 25,000 units of Ultragenyx Pharmaceutical stock on 15 January 2021 worth over $1,375,000. On average, Camille trades about 1,804 units every 45 days since 2018. As of 21 June 2024 he still owns at least 3,000 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Camille Bedrosian stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Camille Bedrosian biography
Dr. Camille L. Bedrosian M.D. serves as Chief Medical Officer and Executive Vice President of the Company. Prior to Ultragenyx, she served as Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc., a biopharmaceutical company, from May 2008 to January 2018. Between September 2002 and April 2008, she served as Vice President and Chief Medical Officer at Ariad Pharmaceuticals, Inc., an oncology company. From 1997 to 2002, Dr. Bedrosian served in the Clinical Research and Development Department of Wyeth/Genetics Institute, Inc., most recently as Senior Director, Oncology/Hematology. From 1986 to 1997, she was a Fellow, an Associate, and then Assistant Professor of Medicine in the Division of Hematology and Oncology at Duke University Medical Center and the Duke Comprehensive Cancer Center. Dr. Bedrosian received her A.B. degree from Harvard University/Radcliffe College in Chemistry, her M.S. in Biophysics from M.I.T., and her M.D. from Harvard Medical School.
What is the salary of Camille Bedrosian?
As the Chief Medical Officer and Executive Vice President of Ultragenyx Pharmaceutical, the total compensation of Camille Bedrosian at Ultragenyx Pharmaceutical is $2,496,820. There are 3 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
How old is Camille Bedrosian?
Camille Bedrosian is 67, he's been the Chief Medical Officer and Executive Vice President of Ultragenyx Pharmaceutical since 2018. There are 3 older and 22 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
What's Camille Bedrosian's mailing address?
Camille's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.
Insiders trading at Ultragenyx Pharmaceutical
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr és Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
What does Ultragenyx Pharmaceutical do?
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
What does Ultragenyx Pharmaceutical's logo look like?
Complete history of Camille Bedrosian stock trades at Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals és Crinetics Pharmaceuticals Inc
Ultragenyx Pharmaceutical executives and stock owners
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include:
-
Emil Kakkis,
President, Chief Executive Officer, Director -
Dennis Huang,
Chief Technical Operations Officer, Executive Vice President -
John Pinion,
Chief Quality Officer and Executive Vice President of Translational Sciences -
Camille Bedrosian,
Chief Medical Officer and Executive Vice President -
Thomas Kassberg,
Chief Business Officer, Executive Vice President -
Karah Parschauer,
Executive Vice President, General Counsel -
Dr. Emil D. Kakkis M.D., Ph.D.,
Pres, CEO & Director -
Shehnaaz Suliman,
Independent Director -
Dr. Camille L. Bedrosian M.D.,
Chief Medical Officer & Exec. VP -
Erik Harris,
Exec. VP & Chief Commercial Officer -
John Richard Pinion II,
Chief Quality Operations Officer & Exec. VP of Translational Sciences -
Daniel Welch,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
William Aliski,
Independent Director -
Michael Narachi,
Independent Director -
Lars Ekman,
Independent Director -
Clay Siegall,
Independent Director -
Deborah Dunsire,
Independent Director -
Mardi C. Dier,
Exec. VP & CFO -
Mardi Dier,
Chief Financial Officer, Executive Vice President -
Ernie Meyer,
Chief Human Resource Officer, Executive Vice President -
Erik Harris,
Executive Vice President and Chief Commercial Officer -
Ernie W. Meyer,
Chief HR Officer & Exec. VP -
Karah Herdman Parschauer J.D.,
Gen. Counsel & Exec. VP -
Danielle Keatley,
Sr. Director of Investor Relations & Corp. Communications -
Dennis Karl Huang,
Chief Technical Operations Officer & Exec. VP -
Theodore A. Huizenga,
VP, Corp. Controller & Principal Accounting Officer -
Sunil Agarwal,
Chief Medical Officer -
Jayson Donald Alexander Dallas,
See Remarks -
Wladimir Hogenhuis,
Chief Operating Officer -
Llc Fmr,
10% owner -
Marten Steen,
Director -
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Amrit Ray,
-
Shalini Sharp,
EVP, Finance -
Corazon (Corsee) D. Sanders,
-
Theodore Alan Huizenga,
SVP, Chief Accounting Officer -
Eric Crombez,
EVP and Chief Medical Officer -
Howard Horn,
Chief Financial Officer